Drug Profile
DT 320
Alternative Names: DT-320Latest Information Update: 11 Sep 2023
Price :
$50
*
At a glance
- Originator University of Oklahoma
- Developer DormaTarg
- Class Antineoplastics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bladder cancer; Breast cancer; Malignant melanoma; Non-small cell lung cancer; Prostate cancer
Most Recent Events
- 11 Sep 2023 Discontinued - Preclinical for Bladder cancer in USA (Intraperitoneal)
- 11 Sep 2023 Discontinued - Preclinical for Breast cancer in USA (Intraperitoneal)
- 11 Sep 2023 Discontinued - Preclinical for Malignant melanoma in USA (Intraperitoneal)